Crinecerfont
Crinecerfont is a corticotropin-releasing factor type 1 (CRF1) receptor antagonist being developed for the treatment of congenital adrenal hyperplasia.
Detailed technical, regulatory, and supply information is available for commercial evaluation.
Technical Overview
Crinecerfont – CAS 752253-39-7
CAS Number
752253-39-7
Category
Congenital Adrenal Hyperplasia (CAH)
Therapeutic Class
CRF1 receptor antagonist
Description
Crinecerfont is a corticotropin-releasing factor type 1 (CRF1) receptor antagonist being developed for the treatment of congenital adrenal hyperplasia.
Applications
- Congenital adrenal hyperplasia
Handling & Supply Details
Packaging
Standard export packaging in double-lined HDPE drums or fiber drums with inner poly liners; custom pack sizes available on request.
Product Inquiry
Disclaimer
Products offered are intended strictly for R&D, registration and/or export purposes only. The responsibility for ensuring that the product does not infringe any third-party patent or intellectual property rights in the destination country rests solely with the buyer.